RT Journal Article
SR Electronic
T1 Is Australia ready for the rollout of amyloid-targeting therapies for Alzheimer’s disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.05.24309974
DO 10.1101/2024.07.05.24309974
A1 Michaelian, Johannes C.
A1 Rowe, Christopher C.
A1 Kurrle, Susan E.
A1 Pond, Constance Dimity
A1 Woodward, Michael
A1 Naismith, Sharon L.
YR 2024
UL http://medrxiv.org/content/early/2024/07/05/2024.07.05.24309974.abstract
AB Background New amyloid-targeting monoclonal antibody (mAb) therapies for Alzheimer’s disease (AD) are currently under review by the Therapeutic Goods Administration for use in Australia.Aims To determine the infrastructure, workforce and training needs of Australian memory and cognition clinics to characterise health system preparedness for amyloid-targeting mAb therapies for AD.Methods A national, cross-sectional online survey of medical specialists was conducted.Results Thirty medical specialists (Geriatricians, n=23; Psychiatrists, n=4; Neurologists, n=3) from 30 different clinics participated (public, 76.7%; private, 23.3%), including metropolitan (73.3%), regional (20.0%) and rural (6.7%) areas. On average, clinics reported assessing 5.4 (SD=3.2) new patients per week, of which 2.4 (range: 0-5) were considered to have Mild Cognitive Impairment (MCI). Only 40% of clinics use biomarkers to assess whether patients with MCI have AD, and 55% have intravenous infusion capability. While the majority of clinicians were confident in their knowledge of mAbs, only 33% felt confident in using these. Identified impediments to clinical implementation included a) lack of real-world experience; b) lack of current Models of Care and appropriate use guidelines; c) current clinic set-up; and d) information about safety.Conclusions Australia’s health system preparedness for amyloid-targeting mAb therapies will require further investment in infrastructure, equity of access, clinician training and support. Long wait-times already impact access to clinics, and with the forecast rise in MCI and dementia cases, services will need to be expanded; while appropriate models of care and clear and efficient inter-sector health pathways will be needed to prepare for the use of mAbs.Competing Interest StatementJCM: Eisai Australia - speaker honorarium; investigator-initiated research grant via the Australian Dementia Network to undertake this work. CCR: Enigma/ Cerveau Technologies - Research grant to institution, Scientific Advisory Board; Biogen - Research grant to institution and Medical Education Working Group; Prothena - Scientific advisory board; Merck - Scientific input consultant; Janssen - Research grant to institution; Eisai Australia - Medical Advisory Board; Lilly Australia - Medical Advisory Board; Roche - speaker honorarium. SEK: Roche - Speaker honorarium MW: Roche - Research grant to institution, Scientific Advisory Board; Biogen - Research grant to institution and Medical Education Working Group; Merck/MSD - Scientific advisory board; Actinogen - Scientific input consultant; Janssen - Research grant to institution; Eisai Australia - Medical Advisory Board; GSK - speaker honorarium SLN: Eisai Australia - Medical Advisory Board & Research grant via the Australian Dementia Network to undertake this work; Roche - speaker honorarium; Nutrica - speaker honorariumFunding StatementThis study was supported by an investigator-initiated research grant from Eisai Australia and we are grateful for their support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The conduct of this study was approved by the University of Sydney's Human Research Ethics Committee (Approval Number: 2023/480).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data for this study will not be shared, as we do not have permission from the participants or ethics approval to do so.